Accenture vs Pfizer: Revenue, Profit and Business Model
Accenture reported $69.7B of revenue in FY2025 and $7.7B of net income. Pfizer reported $62.6B of revenue in FY2025 and $7.8B of net income.
Latest financial snapshot
Financial summary
Accenture
Accenture's fiscal year ends August 31. Revenue rose from $34.80B in FY2016 to $69.67B in FY2025, and net income attributable to Accenture plc rose from $4.11B to $7.68B over the same period. FY2025 brought $80.62B in new bookings, $10.87B of free cash flow, GAAP diluted EPS of $12.15 and $8.3B returned to shareholders through dividends and buybacks. Spending on acquisitions was $6.58B in FY2024 and $1.47B in FY2025. In Q3 FY2026 (to May 31, 2026) revenue was $18.72B, up 6% in U.S. dollars and 3% in local currency, and full-year FY2026 results are due on October 1, 2026.
Pfizer
Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%.
Revenue and profit by year
Accenture
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $69.7B | $7.7B | 11.0% | +7.4% | Source |
| FY2024 | $64.9B | $7.3B | 11.2% | +1.2% | Source |
| FY2023 | $64.1B | $6.9B | 10.7% | +4.1% | Source |
| FY2022 | $61.6B | $6.9B | 11.2% | +21.9% | Source |
| FY2021 | $50.5B | $5.9B | 11.7% | +14.0% | Source |
| FY2020 | $44.3B | $5.1B | 11.5% | +2.6% | Source |
| FY2019 | $43.2B | $4.8B | 11.1% | +5.4% | Source |
| FY2018 | $41B | $4.1B | 9.9% | +13.3% | Source |
| FY2017 | $36.2B | $3.4B | 9.5% | +4.0% | Source |
| FY2016 | $34.8B | $4.1B | 11.8% | — | Source |
Pfizer
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $62.6B | $7.8B | 12.4% | -1.6% | Source |
| FY2024 | $63.6B | $8B | 12.6% | +6.8% | Source |
| FY2023 | $59.6B | $2.1B | 3.6% | -41.1% | Source |
| FY2022 | $101.2B | $31.4B | 31.0% | +24.5% | Source |
| FY2021 | $81.3B | $22B | 27.0% | +95.2% | Source |
| FY2020 | $41.7B | $9.2B | 22.0% | +1.8% | Source |
| FY2019 | $40.9B | $16B | 39.2% | +0.2% | Source |
| FY2018 | $40.8B | $11.2B | 27.3% | -22.3% | Source |
| FY2017 | $52.5B | $21.3B | 40.6% | -0.5% | Source |
| FY2016 | $52.8B | $7.2B | 13.7% | — | Source |
Where the revenue comes from
Accenture
- Consulting
$35.11B in FY2025 revenue
Consulting includes strategy, technology consulting, systems integration, cloud migration, data and AI programs, and large transformation projects.
- Managed Services
$34.57B in FY2025 revenue
Managed Services includes application management, infrastructure operations, business process services, finance operations, customer operations, and other long-term outsourced work.
- AI, Data, and Digital Core
Reported across consulting and managed services
Accenture embeds AI, data, cybersecurity, cloud, enterprise platforms, and digital core modernization into client transformation programs.
- Song, Supply Chain, Engineering, and Talent
Reported across service lines
These capabilities cover customer experience, commerce, design, marketing technology, product engineering, supply chain, workforce transformation, and change management.
Pfizer
- Patented medicines
Core revenue
Prescription drugs protected by exclusivity and clinical differentiation.
- Vaccines
Major revenue contributor
Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.
- Oncology
Strategic growth driver
Cancer medicines, antibody-drug conjugates, and Seagen-related assets.
- Hospital and anti-infective products
Meaningful contributor
Sterile injectables, anti-infectives, and hospital therapies.
- Collaborations and alliances
Supplemental
Co-promoted products and partnered scientific platforms.
Business model and strategy
Accenture
How it makes money
Accenture sells professional services to large companies and governments. Consulting revenue ($35.11B in FY2025) comes from strategy, technology implementation, cloud migration and data and AI projects. Managed services revenue ($34.57B) comes from multi-year contracts to run applications, infrastructure and business processes such as finance or customer operations.
Growth strategy
Accenture grows through a mix of organic services and frequent acquisitions. It spent $6.58B on businesses and investments in FY2024 and $1.47B in FY2025, and in 2026 announced its largest recent deals: Faculty in the UK and the $1.2B Ookla agreement.
Competitive advantage
Accenture can take a client from strategy work through systems implementation and then run the resulting systems or processes under multi-year managed services contracts; in FY2025 managed services was $34.57B of its $69.67B revenue.
Pfizer
How it makes money
Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Revenue is concentrated in large franchises such as Eliquis (co-commercialized with Bristol Myers Squibb), the Prevnar pneumococcal vaccines, the Vyndaqel tafamidis family, Ibrance, Xtandi and the Seagen antibody-drug conjugates.
Growth strategy
Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).
Competitive advantage
Pfizer's advantage is scale in late-stage development, regulatory filings, manufacturing and commercialization. The BioNTech partnership showed it: BioNTech supplied the mRNA science, while Pfizer ran the global Phase 3 trial with more than 40,000 participants, built ultra-cold distribution and manufactured billions of Comirnaty doses.
Questions about Accenture vs Pfizer
Which company has higher revenue — Accenture PLC or Pfizer Inc.?
Accenture PLC reported $69.7B (FY2025), while Pfizer Inc. reported $62.6B (FY2025). By last reported revenue, Accenture PLC is the larger business, with Pfizer Inc. reporting a smaller revenue base.
What is the market cap of Accenture PLC vs Pfizer Inc.?
Accenture PLC's market capitalisation stands at $110.7B, while Pfizer Inc.'s is $160.3B. Pfizer Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Accenture PLC.
Which is more financially efficient — Accenture PLC or Pfizer Inc.?
Accenture PLC generates $87k / employee in revenue per employee, while Pfizer Inc. generates $834k / employee. Pfizer Inc. shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Accenture PLC and Pfizer Inc. make money?
Accenture PLC and Pfizer Inc. generate revenue in fundamentally different ways. Accenture PLC: Accenture sells professional services to large companies and governments. Pfizer Inc.: Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market.
Which company is valued higher relative to revenue — Accenture PLC or Pfizer Inc.?
On a price-to-sales (P/S) basis, Accenture PLC trades at 1.6x P/S and Pfizer Inc. at 2.6x P/S. Pfizer Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Accenture PLC. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Accenture PLC bigger than Pfizer Inc.?
By last reported revenue, Accenture PLC ($69.7B (FY2025)) is the larger company compared to Pfizer Inc. ($62.6B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Accenture vs Pfizer overview